| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8222137 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 5 Pages |
Abstract
Daily oral everolimus (10 mg) combined with both concurrent radiation and temozolomide followed by adjuvant temozolomide is well tolerated, with an acceptable toxicity profile. A randomized phase 2 clinical trial with mandatory correlative biomarker analysis is currently under way, designed to both determine the efficacy of this regimen and identify molecular determinants of response.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Prakash MD, Minhee MA, Patrick Y. MD, Amyn M. MD, PhD, Merideth MD, Thomas A. MD, Benjamin W. MD, Minesh P. MD, FASTRO,